Illumina, Inc. (ILMN) announced on Tuesday the acquisition of Fluent BioSciences, a pioneering company in single-cell technology.
"The integration of Fluent BioSciences into Illumina significantly expands our capabilities, supporting a crucial growth area and advancing our multiomics strategy," stated Steven Barnard, Chief Technology Officer of Illumina. "Single-cell research offers vast potential for new discoveries, and Fluent's innovative, accessible, and flexible single-cell methodology will expedite our delivery of comprehensive multiomics solutions for our customers."
Fluent's technology for single-cell analysis removes the need for intricate, costly instruments and microfluidic consumables.
The acquisition was finalized on July 9, 2024, and was financed through Illumina's available cash reserves.
